Skip to main content
Clinical Trials/NCT04107038
NCT04107038
Completed
Not Applicable

A Randomized Controlled Trial Comparing Monitored Anesthesia Care Versus General Anesthesia With Transesophgeal Echocardiography for Transcatheter Aortic Valve Replacement

Medical University of South Carolina1 site in 1 country170 target enrollmentNovember 22, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Transcatheter Aortic Valve Replacement
Sponsor
Medical University of South Carolina
Enrollment
170
Locations
1
Primary Endpoint
ICU Admission Rate
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

This study is being done to evaluate the impact that monitored anesthetic care (MAC) versus general endotracheal anesthesia (GETA) has on hospital length of stay, rate of ICU admission, and procedural mortality for patients undergoing Transcatheter Aortic Valve Replacement (TAVR). Also, the investigators hope to determine if the use of Transesophageal Echocardiography (TEE) during GETA impacts device success. Adult patients undergoing transfemoral approach TAVR for aortic valve stenosis may be eligible candidates for this study.

Registry
clinicaltrials.gov
Start Date
November 22, 2019
End Date
August 15, 2025
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

George Whitener

Principal Investigator

Medical University of South Carolina

Eligibility Criteria

Inclusion Criteria

  • Adult patients ≥ 18 years old
  • Adult patients undergoing transfemoral approach TAVR for aortic valve stenosis
  • Adult patients who are medically eligible to receive both anesthetics (GA and MAC)

Exclusion Criteria

  • Inability to speak English
  • Body Mass Index (BMI) \> 37 kg/m2
  • History of difficult airway requiring fiberoptic intubation
  • Inability to lie flat
  • Women who are pregnant
  • Patients who have contraindications to either anesthetic, such as an allergy or history of malignant hyperthermia, will also be excluded from the study.
  • Inability or unwillingness of subject to give informed consent based on any reason
  • Patients with any of the following absolute contraindications to TEE:
  • Perforated Viscus
  • Esophageal Stricture

Outcomes

Primary Outcomes

ICU Admission Rate

Time Frame: Up to 48 hours

The investigators will determine the ICU admission rate by taking the total number of patients admitted to the ICU and dividing it by the number of cases in each arm of the study, based on MUSC's "fast track" pathway and our inclusion.

Hospital Length of Stay

Time Frame: Up to 1 month

The total number of hours that the patient stayed in the hospital will be measured from the "Anesthesia Start" time until their time of discharge, as recorded in their electronic medical record.

Procedural Mortality

Time Frame: Up to 30 days

The percentage of the study population that died within 30 days of their procedure or during index procedure hospitalization - if the postoperative length of stay is longer than 30 days.

Secondary Outcomes

  • Paravalvular Regurgitation(For GETA cases, will be recorded after valve implantation. For all cases, will be recorded from a TTE report that is completed on post-operative day 1 or 2 and at 1 year.)

Study Sites (1)

Loading locations...

Similar Trials